ArticleThoracic cancer2026
Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural effusion (MPE) is associated with a poor prognosis and quality of life in patients with non-small cell lung cancer (NSCLC). Additionally, cerebral edema can lead to neurological symptoms that adversely affect activities of daily living. While bevacizumab has demonstrated efficacy in treating both MPE and cerebral edema, there is limited research on ramucirumab, an angiogenesis inhibitor. Therefore, this study aimed to evaluate the efficacy of docetaxel combined with ramucirumab for the management of MPE and cerebral edema.
methodsWe retrospectively analyzed medical records of patients with advanced NSCLC who received docetaxel in conjunction with ramucirumab at Shizuoka Cancer Center between August 2016 and March 2023. The primary endpoints were pleural effusion progression-free survival (PE-PFS) and the cerebral edema control rate. Secondary endpoints included response rate, progression-free survival (PFS), overall survival (OS), and the incidence of toxicities.
resultsA total of 163 patients were included. The median PE-PFS was 8.1 months (95% CI: 4.8-12.0 months). The pleural effusion control rate was 87%, whereas the cerebral edema control rate was 26%. The response rate was 26%, with a median PFS of 4.4 months (95% confidence interval [CI]: 3.7-5.1 months) and a median OS of 11.1 months (95% CI: 9.2-16.0 months). Adverse events leading to discontinuation of treatment occurred in 30% of patients for docetaxel and 33% for ramucirumab, with fatigue being the most common reason for discontinuation.
conclusionDocetaxel plus ramucirumab was effective in controlling pleural effusion but showed limited effects on cerebral edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.